IPO registrations (S-1, F-1) · Registrants

LEXICON PHARMACEUTICALS, INC.

SEC CIK
1062822 · filings on EDGAR ↗
Name on the registration
LEXICON GENETICS INC/TX
Former names
LEXICON PHARMACEUTICALS, INC./DE (2007–2014); LEXICON GENETICS INC/TX (2000–2007)
Registration
Form S-1, first filed 2000-02-09, last 2000-04-06; 1 initial registration, 4 amendments
Outcome
Final prospectus filed 2000-04-07
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
2445 TECHNOLOGY FOREST BLVD., SUITE 1100, The Woodlands, TX 77381
EIN
76-0474169
Ticker
LXRX (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
LEXICON PHARMACEUTICALS, INC. on the corporate pages

Offering terms

Proposed price range
$22.00–$24.00 per share (S-1/A filed 2000-04-06)
Final price
$22.00 per share, within the range (424B4 filed 2000-04-07, an initial public offering)
Shares sold
10,000,000
Gross proceeds
$220,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol LEXG
Lead underwriters
J.P. Morgan; Credit Suisse (3,937,500 shares); CIBC World Markets (1,437,500 shares); Punk, Ziegel & Company, L.P (437,500 shares)
Syndicate
Fahnestock & Co. Inc (50,000); Jackson Securities Incorporated (50,000); Needham & Company (50,000); Raymond James (50,000); Sanders Morris Harris (50,000)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 6

FiledFormWhat it isName as filedEDGAR
2000-02-09S-1S-1 (registration)LEXICON GENETICS INC/TX0000950129-00-000465 ↗
2000-03-01S-1/AS-1/A (amendment)LEXICON GENETICS INC/TX0000950129-00-000879 ↗
2000-03-17S-1/AS-1/A (amendment)LEXICON GENETICS INC/TX0000950129-00-001256 ↗
2000-04-05S-1/AS-1/A (amendment)LEXICON GENETICS INC/TX0000950129-00-001673 ↗
2000-04-06S-1/AS-1/A (amendment)LEXICON GENETICS INC/TX0000950129-00-001709 ↗
2000-04-07424B4424B4 (final prospectus)LEXICON GENETICS INC/TX0000950129-00-001731 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2000-04-06S-1/Aregistration statement$22.00–$24.00$23.0010,000,000$230,000,000Nasdaq LEXG3from the submission text; range, price sentence, shares headline, proceeds computed, cover names 3document ↗
2000-04-07424B4final prospectus$22.0010,000,000$220,000,000Nasdaq LEXG9from the submission text; price sentence, shares headline, proceeds computed, underwriting table 8, cover names 3document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
GREGORY JULIA POfficerEVP and CFO; EVP, Corp Dev and CFO42006–2008
COLBERT WALTER FOfficerSVP, HR and Corp Serv22006–2007
ISHIMOTO LANCE KOfficerSVP, Intellectual Property42006–2008
MAIN ALAN JOfficerEVP, CMC and Supply Operations; EVP, Commercial Supply Ops; EVP, Innov & Chem Sciences; EVP, Pharmaceutical Research; SVP Lex Pharm382006–2025
PIGGOTT JAMES R PHDOfficerSVP of Pharm Bio52006–2008
SANDS ARTHUR TDirector,OfficerPres & CEO; President & CEO162006–2014
WADE JEFFREY LOfficerEVP, Corp Adm Affairs and CFO; EVP, Corp Dev and CFO; EVP, Gen. Counsel; EVP, General Counsel; President and CFO; President and COO432006–2024
ZAMBROWICZ BRIAN POfficerEVP, Chief Scientific Officer; EVP, Research152006–2014
BARKER SAM LDirector342006–2026
CLOHERTY PATRICIA MDirector12006
LEFKOWITZ ROBERT J MDDirector232006–2024
NIES ALAN SDirector222006–2023
Palantoni FrankDirector212006–2023
ROSE CLAYTON STUARTDirector32006–2007
Mills BarryDirector32006–2007
BROWN PHILIP MOfficerSVP Clinical Development; SVP, Clinical Development; VP Clinical Development52007–2010
Wiltsey Kathleen MDirector32007–2009
HOWSON TAMAR DOfficerEVP of Bus Dev22007–2008
DEBBANE RAYMONDDirector; Director,TenPercentOwner; TenPercentOwner482007–2026
Invus Advisors, L.L.C.Director,TenPercentOwner; TenPercentOwner242007–2024
Invus, L.P.Director,TenPercentOwner; TenPercentOwner242007–2024
Invus Public Equities Advisors, LLCDirector,TenPercentOwner; TenPercentOwner202007–2024
Invus Public Equities, L.P.Director,TenPercentOwner; TenPercentOwner202007–2024
Ulys, L.L.C.Director,TenPercentOwner; TenPercentOwner112007–2022
Amouyal PhilippeDirector282007–2026
SOBECKI CHRISTOPHER JDirector302007–2026
Swain Judith LDirector272007–2026person page Fuzzy
Tessmer James FOfficerVP, Finance & Accounting; VP, Finance & Acctg322008–2021
Tragash Steven AlanOfficerVP, Corp Affairs; VP, Corporate Affairs22009–2010
BANSAL AJAYOfficerEVP Corp Dev and CFO22009
Invus C.V.Director,TenPercentOwner; TenPercentOwner62010–2021
Lapuerta PabloOfficerEVP and CMO; EVP, Clin Dev and CMO; EVP, Safety and PV and CMO; SVP, Clin Dev and CMO202011–2020
Artal Group S.A.Director,TenPercentOwner222012–2026
Artal International Management S.A.Director,TenPercentOwner222012–2026
Artal International S.C.A.Director,TenPercentOwner222012–2026
Minne PascalDirector,TenPercentOwner142012–2020
Stichting Administratiekantoor WestendDirector,TenPercentOwner222012–2026
Westend S.A.Director,TenPercentOwner222012–2026
COATS LONNELDirector,OfficerChief Executive Officer; President and CEO312014–2024
NORTHCOTT JOHNOfficerVP, Marketing, Comm Strategy32014–2015
TYLE PRAVEENOfficerEVP, R&D122016–2021
Santini Alexander AOfficerEVP and CCO122016–2020
Crum Brian TOfficerSVP, General Counsel & Secr.; VP, General Counsel & Secr.162019–2026
Artal Treasury LtdDirector,TenPercentOwner12020
Invus Partners, LLCDirector,TenPercentOwner32021–2022
Wittouck AmauryDirector,TenPercentOwner82021–2026
Granowitz Craig BOfficerSVP, Chief Medical Officer112021–2026
Alexander KristenOfficerVP, Finance and Accounting92021–2025
Kassler-Taub Kenneth B.OfficerSVP, Regulatory & QA72021–2024
Seth KiernanOfficerVP, Chief Commercial Officer52021–2023
McDermott WendyOfficerSVP, Human Resources; VP, Human Resources132022–2026
Sullivan Diane E.Director72023–2026
Garner ThomasOfficerSVP, Chief Commercial Officer32023–2024
Exton MichaelDirector,OfficerChief Executive Officer52024–2026
Invus Global Management, LLCDirector,TenPercentOwner22024–2026
Siren, L.L.C.Director,TenPercentOwner22024–2026
Corrigan BrianOfficerSVP, Regulatory & QA32024–2025
DeFrancesco LisaOfficerSVP, IR and Corp Comm; VP, IR and Corp Comm; VP, IR and Corp Strategy52024–2026
Cheung IvanDirector52024–2026
Artal Participations S.a r.l.Director,TenPercentOwner42024–2026
Coiante Scott MOfficerSVP, Chief Financial Officer52025–2026
Martens Rachel YapOfficerSVP, Partnerships & Corp Strat; VP, Partnerships & Corp Strat32025–2026
Gopinathan SumaOfficerSVP, Discovery32025–2026
Avicenna Life Sci Master Fund LPDirector,TenPercentOwner12026
Avicenna Life Sci Master GP LLCDirector,TenPercentOwner12026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2026-02-17LEXICON PHARMACEUTICALS, INC.Pharmaceuticals$59,150,000$55,668,25511
2023-06-20LEXICON PHARMACEUTICALS, INC.Pharmaceuticals$72,215,130$72,215,13011
2022-08-03LEXICON PHARMACEUTICALS, INC.Pharmaceuticals$49,324,650$42,891,00021
2017-03-24LEXICON PHARMACEUTICALS, INC.Pharmaceuticals$10,506,500$10,506,500161
2014-12-12LEXICON PHARMACEUTICALS, INC.Pharmaceuticals$4,662,780$4,662,780161
2014-12-08LEXICON PHARMACEUTICALS, INC.Pharmaceuticals$150,000,000$150,000,00011

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationLexicon Pharmaceuticals, Inc.State business registriesname and state
Business registrationLexicon Pharmaceuticals, Inc.State business registriesname and state
Business registrationLEXICON PHARMACEUTICALS, INC.State business registriesEIN (EXACT, as the state registration reports it)
Business registrationLEXICON PHARMACEUTICALS, INC.State business registriesname and state
Business registrationLEXICON PHARMACEUTICALS, INC.State business registriesname and state
Business registrationLEXICON PHARMACEUTICALS, INC.State business registriesname and state
Business registrationLEXICON PHARMACEUTICALS, INC.State business registriesname and state
Business registrationLEXICON PHARMACEUTICALS, INC.State business registriesEIN (EXACT, as the state registration reports it)
Form 5500 plan sponsorLEXICON PHARMACEUTICALS, INC.EIN (EXACT)
Federal award recipientLEXICON PHARMACEUTICALS, INC.Federal spending (USAspending)name and state
Form D issuerLEXICON PHARMACEUTICALS, INC.Form D private offeringsCIK (EXACT)
Lobbying clientLEXICON PHARMACEUTICALS, INCFederal lobbying (LDA)name and state
Person pageJudith L Swain MdPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)
SEC filerLEXICON GENETICS INC/TXSEC filers (EDGAR)CIK (EXACT)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.